查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717213

药物研发外包市场按服务类型、药物研发阶段、工作流程、药物类型、应用领域和最终用户划分－2025 年至 2030 年全球预测

Drug Discovery Outsourcing Market by Service Type, Discovery Phase, Workflow, Drug Type, Application Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计药物研发外包市场在 2024 年的价值将达到 39.6 亿美元，到 2025 年将以 8.44% 的复合年增长率增长至 42.9 亿美元，到 2030 年将达到 64.5 亿美元。

主要市场统计数据
基准年2024年 39.6亿美元
预计2025年 42.9亿美元
预测年份 2030 64.5亿美元
复合年增长率（%） 8.44%

全球製药业正在快速发展，药物研发外包已成为创新疗法和加快开发时间的关键推动因素。在当今竞争激烈的环境中，企业越来越多地与外部专业组织合作，以利用深厚的科学专业知识、最尖端科技和成本效率。这一策略转变将使公司能够专注于其核心竞争力，同时也使他们能够获得从先进的分析开发到先进的数据分析的广泛技术能力。药物发现的动态性质，加上加强的法律规范和不断增加的研发成本，使得合作成为一种必需品而不是奢侈品。事实证明，外包对于克服传统内部模式中的资源限制和技能分散等挑战至关重要。随着产业努力跟上技术创新的步伐，相关人员也不断适应重视速度、准确性和外部专业知识的市场。业务模式的转变预示着敏捷协作研究新时代的到来，并将药物研发外包定位为下一代治疗开发的基石。这项全面概况有助于深入了解塑造产业未来的趋势和策略见解。

药物研发外包市场的转型

在快速的技术进步和不断发展的科学方法的推动下，药物研发外包生态系统正在经历变革性转变。领先的公司正在采用具有先进分析能力和简化研究流程的数位工具，以缩短将创新治疗方法推向市场所需的时间。传统的研究模式正在被结合自动化、人工智慧和高通量筛检的平台颠覆，实现更准确的预测和更快的决策。随着地理界限变得模糊以及跨区域合作汇集不同的专业知识，全球化发挥关键作用。随着监管要求变得越来越复杂，拥有一个拥有专业知识的外部合作伙伴来遵守严格的标准同时确保资料完整性和合规性变得越来越重要。此外，对个人化医疗和目标主导研究的日益重视迫使公司采用更灵活、敏捷的外包策略。这种转变不仅仅是改变业务策略；这意味着我们必须从根本上重新思考我们如何进行科学发现。这种演变凸显了敏捷的伙伴关係和创新解决方案的必要性，以实现效率和突破性的成果。

药物研发外包的关键细分洞察

全面的细分方法有助于了解药物发现外包市场的细微差别，并强调推动其成长的不同方面。根据服务类型，分析将市场细分为生物服务、化学服务和资料管理服务。在此细分中，生物服务细分为分析开发和生物测试，而化学服务细分为客自订合成和製程研发。透过生物资讯学和数据整合的观点分析资料管理服务，说明资料驱动策略如何支援研究的所有阶段。从发现阶段的角度来看，市场分为先导药物最适化和标靶识别，先导药物最适化进一步分为化合物筛检和基于结构的药物设计，标靶识别分为生物标记发现和基因组序列测定。工作流程细分涵盖了从先导化合物识别和候选化合物优化到临床前开发、标靶识别和筛检，以及最终结合功能资讯学的标靶验证的连续过程。此外，药物类型细分区分大分子和小分子，后者透过生物製药和生物相似药评估的特定领域来考虑。应用细分检查了心血管疾病、感染疾病和肿瘤学等治疗领域，并且在每个领域内，更详细地检查了心血管疾病中的心臟衰竭和高血压、感染疾病中的细菌感染和病毒感染以及肿瘤学中的骨髓恶性肿瘤和固态肿瘤等病理。最后，按最终用户细分，主要集中在合约研究组织、製药和生物技术公司以及研究机构，前者进一步分为全方位服务和专业化模式，后者则与学术机构和政府研究中心形成对比。这种多层次的细分巩固了满足新市场需求和不同相关人员期望的技术框架。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球消费者慢性病盛行率上升
      • 新药和个人化医疗的需求不断增加
      • 全球製药公司研发支出增加
    • 限制因素
      • 外包药物研发过程的高成本
    • 机会
      • 与学术机构持续合作进行药物开发与检验
      • 利用人工智慧和机器学习简化药物发现过程
    • 任务
      • 药物研发外包伙伴关係中对关键流程的依赖风险
  • 市场区隔分析
    • 服务类型：高通量筛检和自动化的创新正在推动对生物服务的需求。
    • 应用领域：心血管疾病领域大量采用外包服务，促进有效治疗方法的开发
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章药物研发外包市场（依服务类型）

  • 生物服务
    • 检测方法开发
    • 生物检测
  • 化学服务
    • 自订合成
    • 製程研究与开发
  • 资料管理服务
    • 生物资讯学
    • 数据集成

第七章 药物研发外包市场（依研发阶段）

  • 先导药物最适化
    • 化合物筛检
    • 基于结构的药物设计
  • 目标识别
    • 生物标记发现
    • 基因测序方法

第八章药物研发外包市场（依工作流程）

  • 潜在客户资格审查和候选人优化
  • 临床前开发
  • 目标识别与筛检
  • 目标检验和功能资讯科学

第九章 药物研发外包市场（以药物类型）

  • 大分子
    • 生物製药
    • 生物相似药
  • 小分子

第 10 章药物研发外包市场（按应用领域）

  • 心血管疾病
    • 心臟衰竭
    • 高血压
  • 感染疾病
    • 细菌感染疾病
    • 病毒感染
  • 肿瘤学
    • 造血系统恶性肿瘤
    • 固态肿瘤

第 11 章药物研发外包市场（依最终用户）

  • 合约研究组织
    • 全方位服务CRO
    • 专业CRO
  • 製药和生物技术公司
    • 大型企业
    • 中小企业
  • 研究机构
    • 学术机构
    • 政府研究中心

12.美洲药物研发外包市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太药物研发外包市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲药物研发外包市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Agilent Technologies Inc.
  • Aragen Life Sciences Ltd.
  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Global, Inc.
  • Dalton Pharma Services
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • GenScript Biotech Corporation
  • HD Biosciences Co., Ltd.
  • IQVIA
  • Jubilant Biosys Ltd.
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Oncodesign Services
  • Personalis, Inc.
  • Pfizer Inc.
  • PPD Inc.
  • Promega Corporation
  • Revvity Discovery Limited
  • Sanofi SA
  • STC Biologics Inc.
  • Syngene International Ltd.
  • TCG Lifesciences Pvt. Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-742BD517D92E

The Drug Discovery Outsourcing Market was valued at USD 3.96 billion in 2024 and is projected to grow to USD 4.29 billion in 2025, with a CAGR of 8.44%, reaching USD 6.45 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.96 billion
Estimated Year [2025] USD 4.29 billion
Forecast Year [2030] USD 6.45 billion
CAGR (%) 8.44%

The global pharmaceutical landscape is evolving rapidly, and drug discovery outsourcing has emerged as a crucial enabler for innovative therapies and accelerated timelines. In today's competitive environment, companies are increasingly partnering with specialized external organizations to leverage deep scientific expertise, state-of-the-art technology, and cost efficiencies. This strategic shift not only allows organizations to focus on their core competencies but also provides access to a broad spectrum of technical capabilities, from advanced assay development to sophisticated data analysis. The dynamic nature of drug discovery, combined with tightening regulatory frameworks and increasing R&D expenditures, makes collaboration a necessity rather than a luxury. Outsourcing has proven essential in overcoming challenges such as resource constraints and fragmented skill sets within traditional in-house models. As the industry strives to maintain its pace of innovation, stakeholders are continuously adapting to a market that prizes speed, precision, and external expertise. The transformation in operational models heralds a new era of agile and collaborative research, positioning drug discovery outsourcing as a cornerstone in the development of next-generation therapeutics. This comprehensive overview sets the stage for a deeper exploration of the trends and strategic insights that are shaping the future of the industry.

Transformative Shifts in the Drug Discovery Outsourcing Landscape

The drug discovery outsourcing ecosystem is experiencing transformative shifts fueled by rapid technological advancement and evolving scientific methodologies. Industry leaders are embracing digital tools that offer enhanced analytic capabilities and streamlined research processes, thereby reducing the time required to bring innovative therapies to market. Traditional models of research are being upended by integrated platforms that merge automation, artificial intelligence, and high-throughput screening, enabling more accurate predictions and faster decision-making. Globalization plays a significant role, as geographical boundaries blur and collaboration across regions brings diverse expertise together. As regulatory requirements become more complex, external partners with specialized capabilities are increasingly critical in navigating stringent standards while ensuring data integrity and compliance. Moreover, the growing emphasis on personalized medicine and target-driven research is compelling organizations to adopt a more flexible and responsive outsourcing strategy. The shift is not merely a change in operational tactics but represents a fundamental rethinking of how scientific discovery is approached. This evolution underscores the need for agile partnerships and innovative solutions geared toward achieving both efficiency and breakthrough outcomes.

Key Segmentation Insights in Drug Discovery Outsourcing

A comprehensive segmentation approach provides a nuanced understanding of the drug discovery outsourcing market, highlighting the diverse facets that drive its growth. An analysis based on service type dissects the market into Biological Services, Chemical Services, and Data Management Services. In this segmentation, Biological Services come with a further breakdown into assay development and biological testing, while Chemical Services are refined into custom synthesis and process R&D. Data Management Services are analyzed through the lenses of bioinformatics and data integration, showing how data-driven strategies support all stages of research. When viewed from the perspective of discovery phase, the market divides into lead optimization and target identification, with lead optimization further categorized into compound screening and structure-based drug design, and target identification split into biomarker discovery and genomic sequencing methods. The workflow segmentation captures a continuum that spans from lead identification and candidate optimization to preclinical development, target identification and screening, and ultimately, target validation paired with functional informatics. Additionally, drug type segmentation distinguishes between large molecules and small molecules, wherein large molecules are examined through the specific areas of biologics and biosimilar evaluation. Application area segmentation explores therapeutic domains such as cardiovascular diseases, infectious diseases, and oncology, with each area further detailed to address conditions like heart failure and hypertension in cardiovascular, bacterial and viral infections in infectious diseases, and hematological malignancies along with solid tumors in oncology. Lastly, segmentation by end user focuses on contract research organizations, pharmaceutical and biotechnology companies, and research institutes, with the former further divided into full-service and specialty models, and the latter contrasting academic institutions against government research centers. This multilayered segmentation solidifies a technical framework that caters to emerging market demands and diverse stakeholder expectations.

Based on Service Type, market is studied across Biological Services, Chemical Services, and Data Management Services. The Biological Services is further studied across Assay Development and Biological Testing. The Chemical Services is further studied across Custom Synthesis and Process R&D. The Data Management Services is further studied across Bioinformatics and Data Integration.

Based on Discovery Phase, market is studied across Lead Optimization and Target Identification. The Lead Optimization is further studied across Compound Screening and Structure-Based Drug Design. The Target Identification is further studied across Biomarker Discovery and Genomic Sequencing Methods.

Based on Workflow, market is studied across Lead Identification & Candidate Optimization, Preclinical Development, Target Identification & Screening, and Target Validation & Functional Informatics.

Based on Drug Type, market is studied across Large Molecules and Small Molecules. The Large Molecules is further studied across Biologics and Biosimillar.

Based on Application Area, market is studied across Cardiovascular Diseases, Infectious Diseases, and Oncology. The Cardiovascular Diseases is further studied across Heart Failure and Hypertension. The Infectious Diseases is further studied across Bacterial Infections and Viral Infections. The Oncology is further studied across Hematological Malignancies and Solid Tumors.

Based on End User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, and Research Institutes. The Contract Research Organizations is further studied across Full-Service CROs and Specialty CROs. The Pharmaceutical & Biotechnology Companies is further studied across Large Enterprises and SMEs. The Research Institutes is further studied across Academic Institutions and Government Research Centers.

Key Regional Trends and Market Dynamics

Global trends in drug discovery outsourcing reveal distinct regional dynamics that influence market strategies and investment decisions. In the Americas, robust infrastructure, high R&D investment, and an integrated ecosystem of biotech startups and established pharmaceutical entities lay the foundation for intensive research collaborations and innovative solutions. This region's strategic focus on digital transformation and regulatory excellence reinforces its position as a global leader in outsourcing partnerships. Across Europe, the Middle East, and Africa, varying economic conditions and regulatory landscapes present both challenges and opportunities. This region benefits from a blend of historical research expertise and emerging biotech hubs, which collectively drive demand for specialized services. Enhanced government initiatives and funding programs are catalyzing industry growth, while partnerships with global research organizations continue to bridge gaps between technology and clinical application. In the Asia-Pacific, rapid economic growth, increasing research expenditures, and a burgeoning talent pool are propelling the market into new frontiers. The region is witnessing strong investments in infrastructure and innovation, which, when paired with competitive cost structures, create an advantageous environment for outsourcing. Each region exhibits unique strengths and practical challenges, yet all demonstrate an unwavering commitment to advancing drug discovery through strategic collaborations and technology-driven processes.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights and Market Leadership

A multitude of companies are setting benchmarks by driving innovation and quality in the drug discovery outsourcing arena. Market pioneers such as Agilent Technologies Inc. and Aragen Life Sciences Ltd. combine deep domain expertise with advanced technological platforms to deliver robust research solutions. Firms like BPS Bioscience, Inc. and Celentyx Ltd. are known for their agile approaches that integrate cutting-edge biological and chemical services, while Charles River Laboratories International, Inc. and Covance, Inc. leverage their extensive global networks to provide comprehensive, end-to-end drug development support. Other players including Crown Bioscience, Inc. and Curia Global, Inc. exemplify how data integration and specialized workflows can enhance research outcomes. Companies such as Dalton Pharma Services and Eurofins Scientific push the boundaries of chemical research with innovative process R&D, whereas Evotec SE and Explicyte are recognized for their prowess in streamlining lead optimization and target identification strategies. Leaders such as GenScript Biotech Corporation and HD Biosciences Co., Ltd. continue to redefine standards within the bioinformatics space with their data-centric approaches. Prominent names including IQVIA and Jubilant Biosys Ltd. are underscored by their vast industry experience and transformative service models. Laboratory Corporation of America Holdings, Merck & Co., Inc., Oncodesign Services, Personalis, Inc., Pfizer Inc., PPD Inc., Promega Corporation, Revvity Discovery Limited, Sanofi S.A., STC Biologics Inc., Syngene International Ltd., TCG Lifesciences Pvt. Limited, Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd. further solidify the competitive landscape with their persistent innovation and collaborative strategies. These organizations are not only aligning with current market needs but are also actively shaping the future of drug discovery outsourcing.

The report delves into recent significant developments in the Drug Discovery Outsourcing Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies Inc., Aragen Life Sciences Ltd., BPS Bioscience, Inc., Celentyx Ltd., Charles River Laboratories International, Inc., Covance, Inc., Crown Bioscience, Inc., Curia Global, Inc., Dalton Pharma Services, Eurofins Scientific, Evotec SE, Explicyte, GenScript Biotech Corporation, HD Biosciences Co., Ltd., IQVIA, Jubilant Biosys Ltd., Laboratory Corporation of America Holdings, Merck & Co., Inc., Oncodesign Services, Personalis, Inc., Pfizer Inc., PPD Inc., Promega Corporation, Revvity Discovery Limited, Sanofi S.A., STC Biologics Inc., Syngene International Ltd., TCG Lifesciences Pvt. Limited, Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders

For industry leaders intent on capitalizing on the evolving landscape of drug discovery outsourcing, a proactive approach is imperative. It is crucial to invest in advanced technologies that enable seamless data sharing, real-time analytics, and automation of complex processes. Embracing digital transformation and integrated platforms can lead to more efficient workflows and improved research outcomes. Strategic partnerships remain a cornerstone of success; collaborating with firms that excel in complementary services can create synergies that drive innovation and reduce time-to-market. Companies should also focus on cultivating agile operational models that quickly adapt to emerging scientific discoveries and regulatory changes. Establishing dedicated centers for digital innovation and continuous upskilling ensures that teams are well-equipped to handle the rapidly shifting paradigms of research. Leaders are encouraged to invest in a robust network of global partners, particularly in regions with unique expertise and cost-effective solutions, to diversify risk and broaden scientific capabilities. Emphasizing quality control, compliance, and transparent communication throughout the outsourced process not only builds trust but also fortifies market reputation. These actionable steps form the cornerstone of a strategy that is both forward-looking and resilient, positioning organizations to thrive amid the complexities of modern drug discovery.

Conclusion: Strategic Navigations in Drug Discovery Outsourcing

In summary, the drug discovery outsourcing market is characterized by rapid innovation and strategic shifts that redefine traditional research paradigms. By leveraging advanced technologies and fostering global collaborations, organizations can navigate the intricacies of modern drug development with confidence. The multi-dimensional segmentation of the market, detailed from service type to end user, provides a granular view that aids in the crafting of targeted strategies. Regional and company-specific insights further highlight the dynamic interplay of technological advancements, regulatory influences, and market demands. As stakeholders continue to adapt to these transformative trends, the emphasis on agility, innovation, and strategic partnerships is more pronounced than ever. This exploration underlines the necessity for a comprehensive, adaptable approach to drive both efficiency and breakthrough results in drug discovery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases among consumers globally
      • 5.1.1.2. Growing demand for novel drugs and personalized medicine
      • 5.1.1.3. Increasing R&D expenditure by pharmaceutical companies worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with outsourcing drug discovery processes
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing partnerships with academic institutions for novel drug development and validation
      • 5.1.3.2. Leveraging AI and machine learning in streamlining drug discovery processes
    • 5.1.4. Challenges
      • 5.1.4.1. Dependency risks over critical processes in drug discovery outsourcing partnerships
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Service Type : Growing demand for biological services due to innovations in high-throughput screening and automation
    • 5.2.2. Application Area : Significant adoption of outsourcing services in cardiovascular diseases to expedite the development of effective treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug Discovery Outsourcing Market, by Service Type

  • 6.1. Introduction
  • 6.2. Biological Services
    • 6.2.1. Assay Development
    • 6.2.2. Biological Testing
  • 6.3. Chemical Services
    • 6.3.1. Custom Synthesis
    • 6.3.2. Process R&D
  • 6.4. Data Management Services
    • 6.4.1. Bioinformatics
    • 6.4.2. Data Integration

7. Drug Discovery Outsourcing Market, by Discovery Phase

  • 7.1. Introduction
  • 7.2. Lead Optimization
    • 7.2.1. Compound Screening
    • 7.2.2. Structure-Based Drug Design
  • 7.3. Target Identification
    • 7.3.1. Biomarker Discovery
    • 7.3.2. Genomic Sequencing Methods

8. Drug Discovery Outsourcing Market, by Workflow

  • 8.1. Introduction
  • 8.2. Lead Identification & Candidate Optimization
  • 8.3. Preclinical Development
  • 8.4. Target Identification & Screening
  • 8.5. Target Validation & Functional Informatics

9. Drug Discovery Outsourcing Market, by Drug Type

  • 9.1. Introduction
  • 9.2. Large Molecules
    • 9.2.1. Biologics
    • 9.2.2. Biosimillar
  • 9.3. Small Molecules

10. Drug Discovery Outsourcing Market, by Application Area

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
    • 10.2.1. Heart Failure
    • 10.2.2. Hypertension
  • 10.3. Infectious Diseases
    • 10.3.1. Bacterial Infections
    • 10.3.2. Viral Infections
  • 10.4. Oncology
    • 10.4.1. Hematological Malignancies
    • 10.4.2. Solid Tumors

11. Drug Discovery Outsourcing Market, by End User

  • 11.1. Introduction
  • 11.2. Contract Research Organizations
    • 11.2.1. Full-Service CROs
    • 11.2.2. Specialty CROs
  • 11.3. Pharmaceutical & Biotechnology Companies
    • 11.3.1. Large Enterprises
    • 11.3.2. SMEs
  • 11.4. Research Institutes
    • 11.4.1. Academic Institutions
    • 11.4.2. Government Research Centers

12. Americas Drug Discovery Outsourcing Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Drug Discovery Outsourcing Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Drug Discovery Outsourcing Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Accenture's strategic investment in 1910 Genetics revolutionizes biopharma drug discovery with AI innovation
    • 15.3.2. Agilent to acquire drug services company BioVectra for close to USD 1 billion
    • 15.3.3. Evotec and Pfizer announce drug discovery collaboration
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agilent Technologies Inc.
  • 2. Aragen Life Sciences Ltd.
  • 3. BPS Bioscience, Inc.
  • 4. Celentyx Ltd.
  • 5. Charles River Laboratories International, Inc.
  • 6. Covance, Inc.
  • 7. Crown Bioscience, Inc.
  • 8. Curia Global, Inc.
  • 9. Dalton Pharma Services
  • 10. Eurofins Scientific
  • 11. Evotec SE
  • 12. Explicyte
  • 13. GenScript Biotech Corporation
  • 14. HD Biosciences Co., Ltd.
  • 15. IQVIA
  • 16. Jubilant Biosys Ltd.
  • 17. Laboratory Corporation of America Holdings
  • 18. Merck & Co., Inc.
  • 19. Oncodesign Services
  • 20. Personalis, Inc.
  • 21. Pfizer Inc.
  • 22. PPD Inc.
  • 23. Promega Corporation
  • 24. Revvity Discovery Limited
  • 25. Sanofi S.A.
  • 26. STC Biologics Inc.
  • 27. Syngene International Ltd.
  • 28. TCG Lifesciences Pvt. Limited
  • 29. Thermo Fisher Scientific Inc.
  • 30. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. DRUG DISCOVERY OUTSOURCING MARKET MULTI-CURRENCY
  • FIGURE 2. DRUG DISCOVERY OUTSOURCING MARKET MULTI-LANGUAGE
  • FIGURE 3. DRUG DISCOVERY OUTSOURCING MARKET RESEARCH PROCESS
  • FIGURE 4. DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG DISCOVERY OUTSOURCING MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS R&D, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA INTEGRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COMPOUND SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STRUCTURE-BASED DRUG DESIGN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GENOMIC SEQUENCING METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & CANDIDATE OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET VALIDATION & FUNCTIONAL INFORMATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOSIMILLAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULL-SERVICE CROS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SPECIALTY CROS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 78. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 82. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 83. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 84. AMERICAS DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 93. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 95. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 96. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 97. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 98. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 102. ARGENTINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 108. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 109. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 110. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 111. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 113. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 114. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 115. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 116. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 119. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 120. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 121. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 123. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 124. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 126. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 127. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 128. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 129. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 131. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 132. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 133. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 134. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 138. CANADA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 139. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 141. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 142. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 143. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 144. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 145. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 146. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 147. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 149. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 150. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 151. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 152. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 156. MEXICO DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 159. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 160. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 162. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 163. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 164. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 165. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 167. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 168. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 169. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 170. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 174. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 175. UNITED STATES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 195. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 198. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 199. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 200. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 201. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 202. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 205. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 206. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 207. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 208. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 209. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 212. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 213. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 215. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 216. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 217. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 218. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 219. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 220. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 221. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 223. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 224. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 225. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 226. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 229. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 230. CHINA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 231. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 233. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 234. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 235. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 236. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 237. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 238. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 239. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 241. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 242. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 243. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 244. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 246. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 247. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 248. INDIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 249. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 251. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 252. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 253. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 254. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 255. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 256. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 257. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 259. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 260. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 261. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 262. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 263. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 264. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 265. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 266. INDONESIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 267. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 269. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 270. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 271. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 272. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 273. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 274. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 275. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 277. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 278. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 279. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 280. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 283. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 284. JAPAN DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 285. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 287. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 288. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 289. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY PHASE, 2018-2030 (USD MILLION)
  • TABLE 290. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, 2018-2030 (USD MILLION)
  • TABLE 291. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, 2018-2030 (USD MILLION)
  • TABLE 292. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW, 2018-2030 (USD MILLION)
  • TABLE 293. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LARGE MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 295. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
  • TABLE 296. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2030 (USD MILLION)
  • TABLE 297. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 298. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 299. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 300. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2030 (USD MILLION)
  • TABLE 301. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 302. MALAYSIA DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 303. PHILIPPINES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. PHILIPPINES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOLOGICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 305. PHILIPPINES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHEMICAL SERVICES, 2018-2030 (USD MILLION)
  • TABLE 306. PHILIPPINES DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT SERVICES, 2018-2030 (USD MILLION)
  • TABLE 307. PHILIPPINES DRUG